Seraphina Therapeutics has exclusive and global licensing rights from the U.S. Navy and the United States of America for commercialization and use of pentadecanoic acid as a supplement, food or beverage ingredient, and pharmaceutical to support human and animal health.
This includes (but is not limited to) use of pentadecanoic acid to: 1) raise pentadecanoic acid blood levels, 2) support energy and fuel homeostasis; cellular energy and fuel homeostasis; cellular health; healthy aging; healthy glucose, triglyceride, cholesterol and insulin levels; and metabolic, heart, liver, skin, sleep, joint, gut, and mood health, 3) prevent and alleviate oxidative stress or a pro-inflammatory state, or 4) prevent and alleviate hyperglycemia, dyslipidemia (high triglycerides or cholesterol), insulin resistance, stress, metabolic syndrome, nonalcoholic fatty liver disease, obesity, type 2 diabetes, cardiovascular disease, anemia, and inflammation.
Beyond the many science-backed indications, our founders’ diligent science has also enabled Seraphina to have exclusive rights from the U.S. Navy and the United States of America around pentadecanoic acid formulations, oral dosing, and targeted body levels. A list of many of the exclusively licensed patents to Seraphina Therapeutics and fatty15, including U.S. and international patents, is available below.
In summary, any entity (other than fatty15 or products licensed by Seraphina Therapeutics) that is marketing or selling pentadecanoic acid as a supplement, ingredient or pharmaceutical within the scope of any of the patented claims is infringing on patents from the U.S. Navy and the United States of America.
